In recent years, a slew of advanced therapy medicinal products (ATMPs), particularly cell and gene therapies, have demonstrated the transformative power of these therapies. CAR-T cell therapy, for example, has revolutionized the field in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma (MM). CAR-T cell application in solid tumors, however, remains elusive due to a variety of challenges in the biology. This not withstanding, results published in 2024 brought renewed optimism for the use of CAR-Ts in solid tumors, by showing that targeting two brain tumor-associated proteins instead of one showed promise
as a strategy for reducing tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer.
